Novartis
NVS Big PharmaSwiss pharma focused on innovative medicines and generics (Sandoz). Leading positions in oncology, ophthalmology, and cardiovascular. Major drugs include Entresto, Cosentyx, and Kisqali.
FDA Novel Drug Designations
(2016-2025)See 17 novel approvals →
Novartis at a Glance
- Strong track record with 95% execution quality across 175 trials
- Fast trial execution (11 months median completion)
Novartis's Key Drugs
Novartis's core commercial portfolio centers on COSENTYX, KISQALI, ENTRESTO, spanning Oncology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
Moderate to severe plaque psoriasis in patients 6 years and older
Breast Cancer
Chronic heart failure in adults
Hypercholesterolemia
Metastatic Castration-Resistant Prostate Cancer
Novartis News
All Novartis news →- Oct 27, 2026 EarningsNovartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance ↗
- Oct 22, 2026 RegulatoryFDA approves Enzeevu (aflibercept-abzv) ↗
- Sep 8, 2026 TrialsNovartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1) ↗
- Sep 4, 2026 TrialsNovartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) ↗
- Sep 1, 2026 TrialsNovartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials ↗
Novartis's Recent FDA Approvals
Novartis secured 13 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
Novartis's Therapeutic Areas
Novartis's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Cardiovascular, across 11 biologic and 90 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Novartis's Top Competitors
Novartis's closest competitors by therapeutic-area and drug-target overlap include Bayer, AstraZeneca, and Boehringer Ingelheim. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Novartis Pipeline Snapshot
Novartis has 1343 active clinical programs from ClinicalTrials.gov — 423 Phase 3, 382 Phase 2 and 538 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 65/67 completed
- • Speed: 11 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (42)
Discontinued (8)
Company Info
- First Approval
- 1942-12-09
- Latest
- 2026-10-30
- Applications
- 784
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges